Andrew Sherwood1, James A Blumenthal, Patrick J Smith, Lana L Watkins, Benson M Hoffman, Alan L Hinderliter. 1. From the Department of Psychiatry and Behavioral Sciences (Sherwood, Blumenthal, Smith, Watkins, Hoffman), Duke University Medical Center, Durham, North Carolina; and Department of Medicine (Hinderliter), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Abstract
OBJECTIVE: To assess the effects of supervised and home-based aerobic exercise training, and antidepressant pharmacotherapy (sertraline) on coronary heart disease (CHD) risk factors in a sample of participants with major depressive disorder (MDD). METHODS: The Standard Medical Intervention versus Long-term Exercise (SMILE)-II study randomized 202 adults (153 women, 49 men) diagnosed as having MDD to one of four interventions, each of 4-month duration: supervised exercise, home-based exercise, antidepressant medication (sertraline, 50-200 mg daily), or placebo pill. Patients underwent a structured clinical interview for depression and completed the Hamilton Depression Rating Scale. CHD risk factors included brachial artery flow-mediated dilation, carotid intima-media thickness, serum lipids, and 10-year atherosclerotic cardiovascular disease (ASCVD) risk. RESULTS: Compared with placebo, active treatment of depression (supervised exercise, home-based exercise, sertraline therapy) was associated with an improvement in CHD risk factors (improved flow-mediated dilation [p = .032], reduced progression of intima-media thickness [p = .037], and a reduction in 10-year ASCVD [p = .049]). The active treatments did not differ from each other in their effects on the CHD risk outcomes. CONCLUSIONS: Both exercise and antidepressant medication improved CHD risk factors and lowered ASCVD risk in patients with MDD. Because MDD is associated with increased risk for CHD events, treatment of depression with exercise or sertraline may reduce the risk of developing CHD in patients with MDD. TRIAL REGISTRATION: Clinical Trials Government Identifier: NCT-00331305.
RCT Entities:
OBJECTIVE: To assess the effects of supervised and home-based aerobic exercise training, and antidepressant pharmacotherapy (sertraline) on coronary heart disease (CHD) risk factors in a sample of participants with major depressive disorder (MDD). METHODS: The Standard Medical Intervention versus Long-term Exercise (SMILE)-II study randomized 202 adults (153 women, 49 men) diagnosed as having MDD to one of four interventions, each of 4-month duration: supervised exercise, home-based exercise, antidepressant medication (sertraline, 50-200 mg daily), or placebo pill. Patients underwent a structured clinical interview for depression and completed the Hamilton Depression Rating Scale. CHD risk factors included brachial artery flow-mediated dilation, carotid intima-media thickness, serum lipids, and 10-year atherosclerotic cardiovascular disease (ASCVD) risk. RESULTS: Compared with placebo, active treatment of depression (supervised exercise, home-based exercise, sertraline therapy) was associated with an improvement in CHD risk factors (improved flow-mediated dilation [p = .032], reduced progression of intima-media thickness [p = .037], and a reduction in 10-year ASCVD [p = .049]). The active treatments did not differ from each other in their effects on the CHD risk outcomes. CONCLUSIONS: Both exercise and antidepressant medication improved CHD risk factors and lowered ASCVD risk in patients with MDD. Because MDD is associated with increased risk for CHD events, treatment of depression with exercise or sertraline may reduce the risk of developing CHD in patients with MDD. TRIAL REGISTRATION: Clinical Trials Government Identifier: NCT-00331305.
Authors: G T O'Connor; J E Buring; S Yusuf; S Z Goldhaber; E M Olmstead; R S Paffenbarger; C H Hennekens Journal: Circulation Date: 1989-08 Impact factor: 29.690
Authors: A Meijer; H J Conradi; E H Bos; M Anselmino; R M Carney; J Denollet; F Doyle; K E Freedland; S L Grace; S H Hosseini; D A Lane; L Pilote; K Parakh; C Rafanelli; H Sato; R P Steeds; C Welin; P de Jonge Journal: Br J Psychiatry Date: 2013-08 Impact factor: 9.319
Authors: Joseph F Polak; Michael J Pencina; Karol M Pencina; Christopher J O'Donnell; Philip A Wolf; Ralph B D'Agostino Journal: N Engl J Med Date: 2011-07-21 Impact factor: 91.245
Authors: N K Wenger; E S Froelicher; L K Smith; P A Ades; K Berra; J A Blumenthal; C M Certo; A M Dattilo; D Davis; R F DeBusk Journal: Clin Pract Guidel Quick Ref Guide Clin Date: 1995-10
Authors: Gillian E Mead; Wendy Morley; Paul Campbell; Carolyn A Greig; Marion McMurdo; Debbie A Lawlor Journal: Cochrane Database Syst Rev Date: 2009-07-08
Authors: Rosa Maria Bruno; Elisabetta Bianchini; Francesco Faita; Stefano Taddei; Lorenzo Ghiadoni Journal: Cardiovasc Ultrasound Date: 2014-08-23 Impact factor: 2.062
Authors: Patrick J Smith; James A Blumenthal; Alan L Hinderliter; Lana L Watkins; Benson M Hoffman; Andrew Sherwood Journal: Am J Geriatr Psychiatry Date: 2018-06-28 Impact factor: 4.105
Authors: Stefanie T LoSavio; Jean C Beckham; Stephanie Y Wells; Patricia A Resick; Andrew Sherwood; Cynthia J Coffman; Angela C Kirby; Tiffany A Beaver; Michelle F Dennis; Lana L Watkins Journal: Contemp Clin Trials Date: 2021-01-08 Impact factor: 2.226
Authors: James A Blumenthal; Patrick J Smith; Andrew Sherwood; Stephanie Mabe; Laurie Snyder; Courtney Frankel; Daphne C McKee; Natalie Hamilton; Francis J Keefe; Sheila Shearer; Jeanne Schwartz; Scott Palmer Journal: Transplant Direct Date: 2020-02-18